Using Magnetocardiography to Diagnose Heart Ischemia
Identification of Myocardial Ischemia With Magnetocardiography Using Single Photon Emission Computed Tomography (SPECT) as a Reference Standard
This study is testing if a new heart imaging technique called Magnetocardiography can accurately detect heart problems in patients who might have a specific type of heart condition.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 228 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Qilu Hospital of Shandong University Academic / other |
| Locations | 1 site (Jinan, Shandong) |
| Trial ID | NCT06255769 on ClinicalTrials.gov |
What this trial studies
This prospective clinical study investigates the effectiveness of Magnetocardiography (MCG) in detecting myocardial ischemia in patients suspected of having non-ST-elevation acute coronary syndrome (NSTE-ACS). The study uses Single Photon Emission Computed Tomography (SPECT) as the gold standard to assess the presence and severity of myocardial ischemia. Patients with symptoms of myocardial ischemia and specific coronary artery conditions will be included, while those with certain contraindications will be excluded. The goal is to determine if MCG can provide reliable diagnostic information comparable to SPECT.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older with symptoms of myocardial ischemia and non-severe coronary artery stenosis.
Not a fit: Patients with severe coronary artery disease, significant comorbidities, or contraindications to SPECT will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could offer a non-invasive and effective method for diagnosing myocardial ischemia, potentially improving patient outcomes.
How similar studies have performed: Previous studies have shown promising results using similar diagnostic approaches, but this specific methodology is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 18 years or older; * Patients with symptoms of myocardial ischemia such as angina pectoris, who have CAG showing \<70% stenosis at the most severe site or CTA showing non-severe stenosis * Signed informed consent. Exclusion Criteria: * Patients with absolute or relative contraindications to SPECT-loaded myocardial perfusion, including acute myocardial infarction within 48 hours, significant left main coronary artery stenosis, bronchial asthma, and adenosine injection allergy; * Patients with Non-ischemic dilated cardiomyopathy, or hypertrophic cardiomyopathy, or moderate or severe valvular disease; * Patients with Hemodynamic instability (systolic blood pressure\<90 mmHg, or who requires vasoactive drugs), or patients with tachyarrhythmia, Ⅱdegree atrioventricular block and above that have not returned to normal; * Patients who have severe renal abnormality with eGFR \<30 ml/min, or patients who are on dialysis; * Patients with malignant tumors with predicted survival of less than 1 year; * Pregnant or breastfeeding women; * Patients who are unable to enter the MCG device, who are unable to perform MCG examination due to interference from metal implants or other reasons, or who are deemed by the investigators to be unsuitable for enrollment.
Where this trial is running
Jinan, Shandong
- Qilu Hospital of Shandong University — Jinan, Shandong, China (Recruiting)
Study contacts
- Principal investigator: Yuguo Chen, Professor — Qliu Hospital of Shandong University
- Study coordinator: Jiaojiao Pang, Doctor
- Email: jiaojiaopang@126.com
- Phone: 0086-0531-82165398
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.